{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:35:39Z","timestamp":1790116539305,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009232","name":"University of Debrecen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009232","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In classical Hodgkin lymphoma (HL), optimizing early risk stratification and response assessment are the cornerstones of therapy. The advanced interpretation of positron emission tomography - computed tomography (PET\/CT) results can provide prognostic information beyond the Deauville score (DS). The aim of our study was to explore the prognostic value of the change in maximum standardized uptake value (\u0394SUVmax) to predict disease progression during the first-line treatment of adult HL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients were treated with curative intent, standard therapy. PET\/CT assessments were performed at baseline, interim and end-of-treatment timepoints. \u0394SUVmax cut-off values were determined by the receiver operating characteristics (ROC) analysis. Overall- (OS) and progression-free survival (PFS) were determined as primary endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline SUVmax did not differ in patients who progressed during or after first-line therapy compared to patients in remission. However, patients with progressive disease had a higher mean SUVmax and lower \u0394SUVmax at interim analysis. The presence of a \u0394SUVmax\u2009&gt;\u200988% after 2 cycles of therapy was associated with longer PFS (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.013 [HR, 5.21]), with a negative predictive value exceeding the DS. The combination of \u0394SUVmax with DS further stratified PET-negative patients: the 5-year PFS of low-risk and high-risk patients were 92.1% and 79.1%, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.047 [HR, 2.87]). The \u0394SUVmax cut-off of 55% in patients with DS 3\u20135 revealed high-risk patients with significantly lower 5-year OS and PFS (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.008 [HR, 13] and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001 [HR, 11.5], respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Altogether, \u0394SUVmax is a promising standalone prognostic marker or combination partner of DS in the early risk stratification and response assessment of HL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40644-025-00904-x","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T04:48:48Z","timestamp":1751345328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["\u0394SUVmax adds prognostic value to early response assessment during the first-line treatment of classical Hodgkin lymphoma: a retrospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"L\u00e1szl\u00f3 Imre","family":"Pincz\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1vid","family":"T\u00f3thfalusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogl\u00e1rka","family":"Dob\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ndor","family":"Barna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bence","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildik\u00f3","family":"Garai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia","family":"Milt\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"15","key":"904_CR1","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2017-10-772665","volume":"131","author":"PJ Br\u00f6ckelmann","year":"2018","unstructured":"Br\u00f6ckelmann PJ, Sasse S, Engert A. Balancing risk and benefit in early-stage classical hodgkin lymphoma. Blood. 2018;131(15):1666\u201378.","journal-title":"Blood"},{"issue":"18","key":"904_CR2","doi-asserted-by":"publisher","first-page":"6565","DOI":"10.1002\/cam4.3298","volume":"9","author":"MPE Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 MPE, Carde P, Viviani S, Bellei M, Fortpied C, Hutchings M, et al. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced hodgkin lymphoma: A pooled analysis of four randomized trials. Cancer Med. 2020;9(18):6565\u201375.","journal-title":"Cancer Med"},{"key":"904_CR3","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano classification lymphoma response criteria in the era of Immunomodulatory therapy. Blood. 2016;128:2489\u201396.","journal-title":"Blood"},{"key":"904_CR4","doi-asserted-by":"crossref","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP et al. Role of imaging in the staging and response assessment of lymphoma: Consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32(27):3048\u201358.","DOI":"10.1200\/JCO.2013.53.5229"},{"issue":"24","key":"904_CR5","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","volume":"25","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746\u201352.","journal-title":"J Clin Oncol"},{"issue":"11","key":"904_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1556\/650.2023.32736","volume":"164","author":"\u00c1 Ill\u00e9s","year":"2023","unstructured":"Ill\u00e9s \u00c1, Garai I, Milt\u00e9nyi Z. Hodgkin-lymphom\u00e1s Betegek Kezel\u00e9s\u00e9vel Szerzett Tapasztalataink. Orv Hetil. 2023;164(11):403\u201310.","journal-title":"Orv Hetil"},{"issue":"2","key":"904_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"16","key":"904_CR8","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9 MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, et al. Early positron emission tomography Response-Adapted treatment in stage I and II hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol. 2017;35(16):1786\u201396.","journal-title":"J Clin Oncol"},{"issue":"10114","key":"904_CR9","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2017","unstructured":"Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, et al. PET-guided treatment in patients with advanced-stage hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German hodgkin study group. Lancet (London England). 2017;390(10114):2790\u2013802.","journal-title":"Lancet (London England)"},{"issue":"12","key":"904_CR10","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1038\/s41375-022-01717-8","volume":"36","author":"J Driessen","year":"2022","unstructured":"Driessen J, Kersten MJ, Visser L, van den Berg A, Tonino SH, Zijlstra JM, et al. Prognostic value of TARC and quantitative PET parameters in relapsed or refractory hodgkin lymphoma patients treated with Brentuximab Vedotin and DHAP. Leukemia. 2022;36(12):2853\u201362.","journal-title":"Leukemia"},{"issue":"21","key":"904_CR11","doi-asserted-by":"publisher","first-page":"6732","DOI":"10.1182\/bloodadvances.2023010404","volume":"7","author":"J Driessen","year":"2023","unstructured":"Driessen J, Zwezerijnen GJC, Sch\u00f6der H, Kersten MJ, Moskowitz AJ, Moskowitz CH, et al. Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed\/refractory hodgkin lymphoma. Blood Adv. 2023;7(21):6732\u201343.","journal-title":"Blood Adv"},{"issue":"4","key":"904_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00259-014-2973-6","volume":"42","author":"M Meignan","year":"2015","unstructured":"Meignan M, Itti E, Gallamini A, Younes A. FDG PET\/CT imaging as a biomarker in lymphoma. Eur J Nucl Med Mol Imaging. 2015;42(4):623\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"904_CR13","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1111\/cas.12282","volume":"104","author":"MK Song","year":"2013","unstructured":"Song MK, Chung JS, Lee JJ, Jeong SY, Lee SM, Hong JS, et al. Metabolic tumor volume by positron emission tomography\/computed tomography as a clinical parameter to determine therapeutic modality for early stage hodgkin\u2019s lymphoma. Cancer Sci. 2013;104(12):1656\u201361.","journal-title":"Cancer Sci"},{"issue":"5","key":"904_CR14","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bjh.18348","volume":"198","author":"M Picardi","year":"2022","unstructured":"Picardi M, Giordano C, Pugliese N, Esposito M, Fatigati M, Muriano F, et al. Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical hodgkin lymphoma: preliminary results of a single-centre phase II study. Br J Haematol. 2022;198(5):847\u201360.","journal-title":"Br J Haematol"},{"key":"904_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejca.2020.03.008","volume":"132","author":"M Picardi","year":"2020","unstructured":"Picardi M, Fonti R, Della Pepa R, Giordano C, Pugliese N, Nicolai E, et al. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and Dacarbazine cycles in advanced-stage hodgkin lymphoma. Eur J Cancer. 2020;132:85\u201397.","journal-title":"Eur J Cancer"},{"issue":"4","key":"904_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2967\/jnumed.113.130609","volume":"55","author":"C Rossi","year":"2014","unstructured":"Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, et al. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in hodgkin lymphoma patients. J Nucl Med. 2014;55(4):569\u201373.","journal-title":"J Nucl Med"},{"issue":"2","key":"904_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00277-019-03892-8","volume":"99","author":"S Yang","year":"2020","unstructured":"Yang S, Qiu L, Huang X, Wang Q, Lu J. The prognostic significance of \u0394suvmax assessed by PET\/CT scan after 2 cycles of chemotherapy in patients with classic hodgkin\u2019s lymphoma. Ann Hematol. 2020;99(2):293\u20139.","journal-title":"Ann Hematol"},{"issue":"5","key":"904_CR18","first-page":"281","volume":"40","author":"T Ribeiro","year":"2021","unstructured":"Ribeiro T, Marques A, Ferreira G, Castro C, Tavares M, Esp\u00edrito-Santo A, et al. Semiquantitative analysis of interim 18F-FDG PET is superior in predicting outcome in hodgkin lymphoma patients compared to visual analysis. Rev Esp Med Nucl Imagen Mol. 2021;40(5):281\u20136.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"3","key":"904_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/jpm13030445","volume":"13","author":"F Ibrahim","year":"2023","unstructured":"Ibrahim F, Gabelloni M, Faggioni L, Padma S, Visakh AR, Cioni D, et al. Are semiquantitative methods superior to Deauville scoring in the monitoring therapy response for pediatric hodgkin lymphoma?? J Pers Med. 2023;13(3):445.","journal-title":"J Pers Med"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00904-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-025-00904-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00904-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:13:28Z","timestamp":1757204008000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-025-00904-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["904"],"URL":"https:\/\/doi.org\/10.1186\/s40644-025-00904-x","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol followed the ethical guidelines of the 1975 Declaration of Helsinki, and ethical approval was obtained from the institutional review board of University of Debrecen, Debrecen, Hungary (IRB number: 4881). Written informed consents were obtained from all patients prior to treatment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}